跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
emtricitabine + tenofovir alafenamide
首页
药物
emtricitabine + tenofovir alafenamide
emtricitabine + tenofovir alafenamide
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
PHARMACEUTICAL FORMULATIONS
申请人: GILEAD SCIENCES INC
优先权: 2015
CN
EP
US
WO
24 件公开
COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV
申请人: JANSSEN SCIENCES IRELAND UNLIMITED CO
优先权: 2017
EP
WO
4 件公开
COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
申请人: GILEAD SCIENCES INC
优先权: 2013
CN
US
2 件公开
Pharmaceutical composition comprising emtricitabine, tenofovir and bicotegravir
申请人: ANHUI BIOCHEM PHARMACEUTICAL CO LTD
优先权: 2022
CN
THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
申请人: GILEAD SCIENCES INC
优先权: 2015
CN
EP
US
9 件公开
Emtricitabine, propofol and tenofovir compound tablet and preparation method thereof
申请人: ANHUI BIOCHEM BIO PHARMACEUTICAL CO LTD
优先权: 2024
CN
METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION
申请人: UNIV HEALTH NETWORK
优先权: 2022
US
HIV post-exposure prophylaxis
申请人: US HEALTH
优先权: 2018
US
药物
反馈
